Semap

Penfluridol

Treatment option:

Medically reviewed

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Semap

Property	Description
Active ingredient	Penfluridol
Form	Oral Long-Acting Depot Tablet
Pharmacological Class	First-Generation Antipsychotic (Neuroleptic)
Origin	Synthetic (Diphenylbutylpiperidine derivative)
General Purpose	Long-term mental stabilization and thought clarity

Semap: Identity and the Antipsychotic Class

Semap is the trade name for the medication containing Penfluridol, a powerful, synthetic active substance. It is fundamentally classified as a first-generation antipsychotic, often termed a typical neuroleptic, and is clinically recognized for its role in the long-term management of chronic conditions requiring continuous mental stabilization. Penfluridol belongs to the diphenylbutylpiperidine derivative group, an established pharmacological class known for its potent action as a dopamine antagonist. This pharmacological action helps modulate imbalances in brain chemistry related to thought and perception.

The Unique Oral Long-Acting Depot Form

The medication is supplied as a tablet uniquely formulated as an oral long-acting depot. This special preparation allows the active ingredient, Penfluridol, to be slowly absorbed after ingestion due to its high lipid solubility. Unlike the majority of oral drugs which necessitate a daily dosing regimen, this depot formulation is specifically designed to enable the slow release of the medication from the body's fatty tissues. This sustained action means the drug provides therapeutic benefits over several days from a single oral dose, a distinctive feature in the field of antipsychotic maintenance therapy.

General Purpose: Stabilizing Thought and Perception

The general purpose of Semap is to help achieve mental stabilization and improved behavioral control in patients, such as those in the maintenance phase of chronic schizophrenia. As a potent D2 dopamine antagonist, Penfluridol's mechanism helps dampen excessive activity, addressing the chemical imbalances often associated with severe psychotic symptoms. This sustained therapeutic presence over an extended duration is intended for individuals requiring reliable, continuous support in maintaining clearer and more organized thought patterns.

What side effects are possible with Semap?

Possible Side Effects and Safety Information

The safety profile of Semap (Penfluridol) is formally documented by regulatory authorities, classifying adverse reactions by system affected and expected frequency. The most frequently observed effects generally involve the nervous system, including drowsiness, sedation, and various Extrapyramidal Symptoms (EPS), such as motor disturbances, tremors, or rigidity.

Other commonly documented effects relate to metabolic and endocrine systems, such as weight gain and hyperprolactinemia, and to the gastrointestinal system, often presenting as constipation or dry mouth.

Serious Adverse Reactions

The official labeling highlights rare but serious adverse reactions, including the risk of Neuroleptic Malignant Syndrome (NMS), a potentially life-threatening condition marked by fever and muscle rigidity. Long-term exposure is associated with the risk of developing Tardive Dyskinesia, a form of potentially irreversible Extrapyramidal Symptoms. Furthermore, as with the antipsychotic drug class, the profile notes the potential for QT prolongation, which can lead to serious cardiac arrhythmias, and an increased risk of blood clotting disorders (Venous Thromboembolism).

Population and Exposure Safety Notes

The safety profile is contextualized by duration; for instance, sedation may be more pronounced during the initial phase of treatment, while the risk of irreversible EPSE is linked to long-term exposure. Specific safety considerations are documented for certain populations, including a warning about the increased risk of death associated with the use of this class of medication in older adults with dementia. Caution is also required in individuals with pre-existing heart conditions or impaired liver function, and use during pregnancy and breast-feeding is generally discouraged.

Overdose and Emergency Response

Semap Overdose and When to Seek Help

The official regulatory documentation defines the Penfluridol overdose profile based on specific clinical manifestations and mandated emergency actions. Overdose presentations documented by health authorities typically affect the central nervous system and the cardiovascular system.

Officially listed manifestations include a diminished state of consciousness, described as reduced awareness, along with motor disturbances such as muscle rigidity, and observable blood pressure abnormalities. The most severe outcome explicitly documented in the regulatory labeling is the risk of serious heart problems, which classifies the overdose as potentially life-threatening.

Due to this documented critical cardiovascular risk, regulatory guidance requires that immediate medical attention must be sought. It is an official mandate to tell a doctor or emergency department immediately upon the suspicion of an excessive dose.

The required management approach is strictly symptomatic and supportive, as official prescribing information states that no specific antidote is known. This procedural management includes necessary steps such as providing support for vital functions and initiating continuous cardiac monitoring. The mandated monitoring reflects the gravity of the documented cardiovascular complications until the patient is clinically stable. This information is derived exclusively from government-authorized documents, outlining the severity and necessary emergency response.

Therapeutic Uses of Semap

This medication is primarily used in the therapeutic domain of chronic schizophrenia and related psychotic illnesses, which are conditions characterized by persistent or recurring symptom patterns. Semap is commonly used for long-term maintenance therapy to sustain stability in adults. It is applied in addressing symptomatic manifestations that interfere with daily functioning, such as hallucinations, delusions, and severe disorganized thinking. The medication helps to ease the overall burden of these symptoms and supports long-term mental stabilization.

The key benefit of its long-acting oral formulation is its role in supporting consistency for patients. This contributes to managing the risk of relapse by helping to maintain the level of improvement previously achieved, assisting patients to cope more steadily with their condition. The simplified regimen is designed to support adherence to treatment, which is relevant for maintaining continuous stabilization.

Quick Fact: Relief for Chronic Psychotic Symptoms Semap is relevant in clinical scenarios where symptoms may become intense or disruptive over time, and a continuous, simplified regimen is needed to promote stability and support relapse prevention.

Regulatory References

Dutch Medicines Evaluation Board Public Assessment Report

Eligibility and Restrictions for Use

Eligibility Map: Who Can and Cannot Use Semap — Official Regulatory Information

Category	Official Regulatory Status
Populations for whom use is allowed	Adults only, for maintenance treatment of schizophrenia.
Populations for whom use is contraindicated	Patients with known hypersensitivity to penfluridol or excipients; those in a coma or with pre-existing severe Central Nervous System (CNS) depression.
Age-related eligibility rules	Use is not established in the pediatric population (children and adolescents). Older adults require special caution.
Condition-specific restrictions	Caution is required for patients with pre-existing heart diseases, a history of seizures/epilepsy, hepatic impairment (liver disease), renal impairment (kidney disease), or uncorrected low potassium (hypokalaemia).
Pregnancy and lactation status	Pregnancy: Use is generally not recommended or restricted. Breastfeeding: Generally discouraged during treatment.

Resulting Eligibility Structure

Official regulatory documents define the eligibility profile by explicitly restricting use to adults in the maintenance phase of treatment. The drug is contraindicated for populations with compromised CNS function or known hypersensitivity, classifying these as absolute exclusions. Other populations, including the elderly and patients with pre-existing cardiovascular, liver, or kidney conditions, may use the medicine only with caution as detailed in the official label, while use in children is not established.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Official regulatory information for Semap (Penfluridol) establishes clear restrictions based on documented interaction patterns. These constraints fall into categories defined by pharmacokinetic (PK) and pharmacodynamic (PD) effects, as well as specific substance restrictions.

Interaction Classifications

Interaction Type	Officially Documented Pattern
Contraindicated PD Combinations	Co-administration is prohibited with Torsadogenic drugs and Dopaminergic agents (except where necessary for Parkinsonian symptoms).
Exposure-Altering PK Risk	Hepatic Enzyme Inhibitors may increase Penfluridol plasma concentrations, while Hepatic Enzyme Inducers may decrease them, both altering drug exposure.
Additive CNS Effects	The combination with other CNS Depressants is restricted due to the documented risk of additive sedative effects and complications like impaired consciousness.

Official Restrictions and Constraints

Non-Medicinal Restriction: Consumption of alcohol is strongly and officially discouraged throughout the entire treatment period.
Population-Specific Note: Liver disease requires specific consideration, monitoring, and potential dosage adjustment, as altered drug clearance may intensify exposure-related interactions.

Regulatory documents define a profile centered on avoiding critical additive risks (PD) and managing changes to drug levels (PK) to ensure consistent therapeutic presence. These statements reflect mandatory prohibitions and constraints for maintaining the defined interaction profile.

Mechanism of Action

How Semap Works

Semap works by selectively engaging a defined receptor system within key biological pathways. This targeted binding acts as a molecular switch, initiating a cascade that modulates overactive or dysregulated physiological processes. This action influences core mechanisms through the suppression of excessive signaling or by adjusting activity within the pathway.

Following initial receptor engagement, Semap directly participates in signal transduction cascades. The drug dampens heightened pathway activation by modifying early molecular steps within central and/or peripheral pathways. This action modulates processes driven by distinct, often excessive, signaling patterns.

The combined molecular action ultimately modulates systemic activity. Through the reduction of excessive mediator activity and adjustment of pathway dynamics, the mechanism induces the stabilization of overactive physiological responses. This targeted pathway adjustment results in defined physiological effects.

Dosage and Administration Information

Instruction Map: How to use Semap — official administration guidelines

Administration scope

Property	Instruction
Route of administration	Oral route, swallowed with a little water.
Dosing schedule	For adult maintenance therapy, the dosage is individualized; common weekly regimens range from 40 mg to 80 mg.
Timing in relation to meals (if applicable)	May be taken with or without food.
Preparation requirements (if applicable)	Tablets may be manufactured as scored tablets, allowing the dose to be divided to assist with fine-tuning during titration.
Age-group administration rules	The medicine is designated for use in adult patients.
Missed-dose rules	If a weekly dose is missed, the protocol indicates not to take a double dose; the regimen is resumed with the next dose on the usual day.
Special procedural conditions	The medicine is designated solely for long-term maintenance treatment and is not indicated for the initial or acute stabilization of symptoms.

Instruction classifications (high-level)

Property	Classification
Administration method type	Oral
Frequency pattern	Weekly (single dose every seven days)
Use-context constraints	Long-term maintenance treatment only.

Resulting procedural structure

Official step sequence:

The starting dose is introduced and titrated over time based on the response to reach the correct maintenance level.
The established therapeutic dose is given as a single oral tablet once per week.
Administration occurs on a consistent day each week to maintain stable therapeutic concentrations.

Connection to the overall use protocol: The official instructions establish a structured, low-frequency protocol defined by the drug's oral long-acting depot formulation. This regimen requires initial titration to determine the appropriate weekly maintenance dose and is constrained to the context of long-term management in adult patients. The clinical protocol utilizes a stable, once-weekly schedule rather than daily administration, which defines the core procedural pattern of this medicine.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Semap (Penfluridol)

This overview summarizes the research evidence and study landscape for Semap (Penfluridol), focusing on information reported in official regulatory documents and peer-reviewed scientific literature. The purpose is to describe what research has been conducted and what patterns have been observed, not to provide clinical advice or personal recommendations.

Evidence for Use in Chronic Schizophrenia and Psychotic Illnesses

The primary research for Penfluridol has focused on its role in exploring long-term mental health maintenance for adults living with chronic psychotic conditions, such as schizophrenia. The evidence base includes findings compiled from systematic reviews (such as Cochrane analyses) and Randomized Controlled Trials (RCTs). These studies typically compare Penfluridol against an inactive substance (placebo) or against other older antipsychotic medications. Studies reported measurements of outcomes related to stability, and some findings described patterns where the drug's use was associated with measurements of longer intervals of time compared to placebo. These findings contribute to understanding symptom patterns studied in adult populations requiring continuous support.

Long-Term Studies and Follow-up Data

Research has explored outcomes over extended periods, focusing on patterns associated with relapse and measurements of long-term outcomes. Studies have monitored patients for medium-term (several months) up to long-term (more than one year) periods. Research describes patterns observed in the studies related to continuous support, and some data indicated that the maintenance use of the drug was associated with measurements of lower rates of all-cause discontinuation in the observed studies.

Evidence Gaps and Areas of Uncertainty

The research landscape contains several limitations. A notable portion of the research was conducted in the 1970s and 1980s, meaning the evidence quality varies across studies due to older methodologies. There is a lack of consistent, detailed reporting on certain modern, patient-relevant measures, such as quality of life and specific measures of cognitive and daily functional status. Furthermore, comparative evidence (head-to-head trials) is often limited when comparing Penfluridol against newer, second-generation antipsychotics. Data for certain subgroups, like children or those with complex co-existing medical conditions, remains insufficient, which means the ability to generalize the findings to all types of patients remains limited.

Key Studies & References Dutch Medicines Evaluation Board Public Assessment Report (PAR) for Penfluridol

Frequently Asked Questions (FAQ)

Common questions about Semap (FAQ)

Q: Does Semap cause weight gain or weight loss?

According to official product information, weight gain is listed as a commonly documented side effect associated with Semap use. Weight loss is not listed in the official safety profile as a possible effect of the medication. Effects on weight are noted in regulatory information as a potential metabolic change.

Q: Does Semap affect fertility in men or women?

Official safety documents note that Semap may cause certain side effects related to reproductive health. These documented effects can include impotence and frigidity in men and missed periods (amenorrhea) in women. These effects are noted in the safety profile as they relate to changes in the endocrine system.

Q: Is Semap a type of steroid or hormone?

Semap is classified as a First-Generation Antipsychotic, often referred to as a neuroleptic, and is not a steroid. While the medicine is not a hormone itself, official information notes that the medication does influence the body's endocrine system.

Q: Does Semap interact with common over-the-counter pain relievers?

Official warnings caution against combining Semap with substances classified as CNS Depressants (Central Nervous System depressants) due to the risk of additive sedative effects. The regulatory information organizes interactions by drug class. Patients are directed by product information to consult the official documentation for all active ingredients in any over-the-counter medicine.

Q: What does 'contraindicated' mean in the context of Semap?

The term contraindication means that, according to the official regulatory label, using the medicine is absolutely prohibited under certain specific medical conditions or in combination with particular substances. This indicates that using the drug under those conditions is not permitted due to safety concerns defined in the official label.

Q: Can Semap cause changes in mood or anxiety levels?

Semap is used for long-term mental stabilization, and its intended action is to modulate thought and perception. Official information notes that its use is associated with measurements of a reduction in symptoms like paranoia and mood swings.

Q: Can Semap be crushed, split, or chewed?

The official instructions state that the tablet should be swallowed whole with a small amount of water. While the tablets may be scored, allowing them to be divided to assist with dose adjustment, crushing or chewing the long-acting formulation may alter the release profile of the medicine and is not recommended.

Q: How is Semap eliminated from the body?

Semap is an oral long-acting drug due to its high lipid solubility. Official regulatory information highlights that the medicine has a long elimination half-life of up to one week. This specific half-life defines the long duration of its therapeutic action, which is why it is given as a once-weekly dose.

Q: How long does it take for Semap to start working after the first use?

Semap is designed for long-term maintenance treatment and has a long half-life, meaning the therapeutic effect builds up gradually. A stable concentration, which is key to its effect, is generally reached gradually after multiple weekly doses.

Q: What happens in the body when Semap is stopped?

Official warnings note that abrupt discontinuation of the medicine without supervision may lead to adverse outcomes. Abrupt discontinuation of Semap may lead to the return or relapse of the original symptoms it was used to manage.

Q: What are the official warnings about driving or operating machinery while on Semap?

Official safety warnings advise against performing activities that require high mental alertness, such as driving a vehicle or operating heavy machinery. Official information states that the use of the medicine may be associated with blurred vision or dizziness, which could impair the ability to perform high-alert activities.

Q: What is the risk of dependence or addiction with Semap?

According to official safety information, Semap is generally not considered to be habit-forming or associated with addiction. Official product information notes that, as with all prescription medications, its use is intended to be under the direction and supervision of a healthcare professional.

Q: How is Semap usage monitored by healthcare professionals, and are special tests needed?

Official safety guidelines indicate that monitoring of the treatment is required, especially during dose adjustment. Monitoring may include specific checks such as an electrocardiogram (ECG) to detect potential heart issues. Clinical monitoring by a healthcare professional is generally included to assess the drug's effects and the patient's condition.

How should Semap be stored and disposed of?

Storage and Disposal of Semap (Penfluridol)

The storage and handling of Semap tablets must follow specific regulatory requirements to maintain their stability.

Storage Conditions

Temperature: Store the tablets at controlled room temperature, specifically between 15 C and 30 C.
Expiration: Do not use the medication after the expiry date printed on the carton.
Child Safety: Semap must be stored strictly out of the reach and sight of children.